Dyne Therapeutics, Inc.

Informe acción NasdaqGS:DYN

Capitalización de mercado: US$2.6b

Dyne Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Dyne Therapeutics de 37.5% y 61.5% por año respectivamente. Se prevé que el BPA crezca en un 40.8% al año. Se espera que la rentabilidad financiera sea de -338.3% en 3 años.

Información clave

37.5%

Tasa de crecimiento de los beneficios

40.75%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.5%
Tasa de crecimiento de los ingresos61.5%
Rentabilidad financiera futura-338.28%
Cobertura de analistas

Good

Última actualización20 May 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Seeking Alpha • Dec 10

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Summary Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one year, providing financial flexibility for late-stage trials and regulatory submissions. DYNE-101 and DYNE-251 both show promising safety and efficacy data, with potential accelerated FDA submissions targeted for late 2026. With a $2.6B market cap and strong liquidity, DYN is positioned for multiple upcoming catalysts, though dual pipeline advancement will increase cash burn. Read the full article on Seeking Alpha
Artículo de análisis • Jun 17

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 13

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Summary Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1, expected in the 1st half of 2026. With positive data released from phase 1/2 ACHIEVE study, plus FDA allowing splicing correction as a surrogate biomarker, it sets up a possible Accelerated Approval filing of DYNE-101 in 2026. It is said that the global Myotonic Dystrophy treatment market could reach $2.78 billion by 2033. Read the full article on Seeking Alpha
Artículo de análisis • Feb 28

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 24

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Summary Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. The company is advancing two primary candidates that have the potential to be approved over the next few years. The stock has fallen significantly recently as have myriad clinical stage concerns over the past few months. An updated analysis around Dyne Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Artículo de análisis • Nov 12

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Dyne...
Seeking Alpha • Nov 11

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Summary Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors. DYN’s current cash runway of 3.5 years mitigates dilution risks, though further funding might be necessary if expenses ramp up with late-stage clinical trials. Despite recent leadership changes causing a stock selloff, DYN's strong cash position and potential in DMD present a speculative “Buy” opportunity ahead of its November 13 earnings report. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Summary Dyne Therapeutics, Inc. experienced a dramatic rise from $6.5 to $46 per share in 2024 followed by a sharp 45% drop to ~$24, now stabilizing at ~$34. The company's IPO in September 2020 raised $268m, focusing on therapeutics for muscle diseases like DM1, DMD, and FSHD. Positive Phase 1/2 trial results for DYNE-101 and DYNE-251 spurred the stock's surge, showing significant improvements in splicing correction and dystrophin expression. Recent volatility raises questions about a “buy the dip” opportunity or the end of Dyne's bull run, amid ongoing clinical trials and fundraising efforts. Read the full article on Seeking Alpha
Artículo de análisis • Aug 14

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • May 21

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Summary Dyne Therapeutics stock rallied 27% after reporting positive results from the DELIVER and ACHIEVE trials. DYNE-101 showed dose-dependent benefits in patients with myotonic dystrophy type 1, indicating disease-modifying potential. DYNE-251 demonstrated positive results in the treatment of Duchenne muscular dystrophy, but long-term safety data is still needed. Financially, Dyne is strong, planning a $300 million public offering to extend its cash runway. I maintain a "hold" on DYN stock; it fits well in a barbell investment strategy for high-risk/high-return portfolio allocation. Read the full article on Seeking Alpha
Artículo de análisis • May 04

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 05

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Summary Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033. Results from the phase 1/2 DELIVER study, using DYNE-251, for the treatment of patients with Duchenne Muscular Dystrophy, expected in H2 2024. The global Duchenne Muscular Dystrophy treatment market is expected to reach $4.32 billion by 2029. Read the full article on Seeking Alpha
Artículo de análisis • Dec 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Aug 09

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Mar 26

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Dec 10

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Aug 26

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 12

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics (NASDAQ:DYN), a clinical-stage biotech focused on muscular diseases, said on Tuesday that health authorities in New Zealand cleared a clinical trial application to start a Phase 1/2 for DYNE-101, an experimental therapy for myotonic dystrophy type 1 (DM1). DM1 is a rare genetic disease characterized by its impact on skeletal, cardiac, and smooth muscle. The multiple ascending dose trial is expected to start dosing patients in mid-2022, the company said, noting that more countries could greenlight DYNE-101 as the trial expands globally, targeting about 60 to 70 adult patients with DM1 The decision from the New Zealand Medicines and Medical Devices Safety Authority marks the “first regulatory clearance for DYNE-101, an important milestone in our efforts to execute our planned global clinical trial for people living with DM1,” Chief Executive of Dyne (DYN) Joshua Brumm said. Wall Street stands strongly behind the prospects of Dyne (DYN) with four Buy ratings and no Hold or Sell ratings.

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:DYN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2028285-417-364-4079
12/31/202751-539-482-49913
12/31/2026N/A-523-486-48013
3/31/2026N/A-452-462-442N/A
12/31/2025N/A-446-424-403N/A
9/30/2025N/A-424-397-376N/A
6/30/2025N/A-413-362-360N/A
3/31/2025N/A-367-323-320N/A
12/31/2024N/A-317-295-292N/A
9/30/2024N/A-295-244-243N/A
6/30/2024N/A-258-220-219N/A
3/31/2024N/A-257-220-220N/A
12/31/2023N/A-236-189-188N/A
9/30/2023N/A-208-184-182N/A
6/30/2023N/A-189-176-175N/A
3/31/2023N/A-177-152-150N/A
12/31/2022N/A-168-157-154N/A
9/30/2022N/A-181-157-153N/A
6/30/2022N/A-182-141-137N/A
3/31/2022N/A-160-157-152N/A
12/31/2021N/A-149-123-120N/A
9/30/2021N/A-126-114-112N/A
6/30/2021N/A-97-98-96N/A
3/31/2021N/A-77-59-58N/A
12/31/2020N/A-59-48-47N/A
9/30/2020N/A-36-32-30N/A
6/30/2020N/A-28-23-22N/A
3/31/2020N/A-21-18-17N/A
12/31/2019N/A-15N/A-12N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que DYN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que DYN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que DYN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (61.5% al año) de DYN crezcan más rápidamente que los del mercado US (11.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (61.5% al año) de DYN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: DYN se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/20 18:17
Precio de las acciones al final del día2026/05/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Dyne Therapeutics, Inc. está cubierta por 21 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Brian SkorneyBaird
William PickeringBernstein
Keay NakaeChardan Capital Markets, LLC